ALLERGY TREATMENT MARKET ANALYSIS

Regional Analysis

To learn more about this report, request sample copy

North America remains the dominant region in the global allergy treatment market and is estimated to hold 38.5% of the market share in 2024. Strong uptake of allergy immunotherapy and the wide availability of generic drugs have supported market growth. The region is home to most leading global pharmaceutical companies with large allergy portfolios. These companies carry out extensive R&D activities and frequently introduce new products, ensuring patients have access to the latest treatment options. Additionally, high awareness regarding allergies and their management has eased treatment-seeking behavior. However, price controls pose pricing challenges, pushing manufacturers to offer value-based offerings.

Asia Pacific is expected to record the highest growth, led by China, India and other developing nations. This can be attributed to improving healthcare infrastructure, rapid economic expansion, and growing medical tourism in these countries. Greater exposure to pollutants and changing lifestyles have contributed to rising allergy prevalence. Local manufacturers are strengthening their generic drug production to meet the needs of price-sensitive consumers. Over-the-counter drugs are also more accessible due to lenient regulations. This has boosted self-medication and made first-line therapies more affordable. International players are focusing on these emerging markets by tying up with local partners or setting up own manufacturing facilities. They view it as a high-potential region to tap into future demand.